| Autor: |
El Farissi M; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., Mast TP; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., van de Kar MRD; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., Dillen DMM; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., Demandt JPA; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., Vervaat FE; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., Eerdekens R; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., Dello SAG; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., Keulards DC; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., Zelis JM; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., van 't Veer M; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.; Department of Biomedical Engineering, Eindhoven University of Technology, 5612 AZ Eindhoven, The Netherlands., Zimmermann FM; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands., Pijls NHJ; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.; Department of Biomedical Engineering, Eindhoven University of Technology, 5612 AZ Eindhoven, The Netherlands., Otterspoor LC; Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands. |
| Abstrakt: |
The timely revascularization of an occluded coronary artery is the cornerstone of treatment in patients with ST-elevation myocardial infarction (STEMI). As essential as this treatment is, it can also cause additional damage to cardiomyocytes that were still viable before reperfusion, increasing infarct size. This has been termed "myocardial reperfusion injury". To date, there is still no effective treatment for myocardial reperfusion injury in patients with STEMI. While numerous attempts have been made to overcome this hurdle with various experimental therapies, the common denominator of these therapies is that, although they often work in the preclinical setting, they fail to demonstrate the same results in human trials. Hypothermia is an example of such a therapy. Although promising results were derived from experimental studies, multiple randomized controlled trials failed to do the same. This review includes a discussion of hypothermia as a potential treatment for myocardial reperfusion injury, including lessons learned from previous (negative) trials, advanced techniques and materials in current hypothermic treatment, and the possible future of hypothermia for cardioprotection in patients with STEMI. |
